Europe accounted for an 18.7% share of global clinical trials activity in 2019, a decrease of 7.6% compared with a 26.3% average over the last ten-years, according to GlobalData.
In Europe, single country studies held a 69.9% share for all clinical trials in 2019, compared with the ten-year average of 68.7%. Multinational trials accounted for a 30.1% share in 2019 against an average of 31.3% in the last ten years.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry-sponsored trials outnumber non-industry-sponsored trials in Europe
Industry-sponsored trials held a 63.7% share of all the clinical trials in Europe in 2019, a rise over their ten-year average of 60.4%. Non-industry-sponsored trials accounted for a 36.3% share in 2019, down from an average of 39.6% in the last ten years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2019 industry-sponsored clinical trials in Europe – Top therapy areas
Oncology was the leading therapy area for industry-sponsored clinical trials in Europe in 2019 with a 26.3% share, remaining flat over its ten-year average of 26.3%.
Central nervous system held a 14.0% share in 2019, staying very close to its ten-year average of 14.2%.
In the third place was infectious disease with a 9.6% share in 2019, down from its ten-year average of 10.8%. Metabolic disorders recorded an 8.3% share in 2019, a drop over its ten-year average of 9.0%.
With a share of 7.4% in 2019, respiratory witnessed a drop over its ten-year average of 7.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry-sponsored clinical trials in Europe by top therapy areas
Central nervous system was the leading therapy area for non-industry-sponsored clinical trials in Europe in 2019 with a 26.4% share, up from a ten-year average of 23.9%.
In the second place was oncology with a 20.5% share in 2019, which represented a rise over a ten-year average of 19.1%.
With a share of 10.9% in 2019, cardiovascular saw a drop over its ten-year average of 14.0%. Infectious disease held an 8.1% share in 2019, as against ten-year average of 10.0%.
Metabolic disorders held a 7.5% share, which was down from ten-year average of 8.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
2019 clinical trials in Europe by phase
In terms of phases, Phase II trials led the industry-sponsored clinical trials in Europe in 2019, with a share of 38.9%, marking a rise over a ten-year average of 36.7%.
Phase I trials stood next with a 25.1% share in 2019, which was up against a ten-year average of 20.8%.
In the third place was Phase III trials with a 24.5% share in 2019, down from its ten-year average of 26.5%.
Phase IV trials held an 11.5% share in 2019, with a more than four percentage point drop over its ten-year average of 15.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry-sponsored clinical trials in Europe, Phase II trials held a leading share of 54.1% in 2019, marking a moderate jump over its ten-year average of 44.8%.
In the second place was Phase IV trials that held a 25.4% share in 2019, saw a more than eight percentage point drop over a ten-year average of 33.9%.
Phase III trials stood at 14.2% share, comparable to its ten-year average of 14.8%.
Phase I trials held a 6.3% share in 2019, within the range of its ten-year average of 6.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
